Química medicinal

An Innovative Complex of Benzene-Poly-Carboxylic Acid and Molybdenum, for Prevention and Treatment of Radiation Dermatitis

Abstract

Fuad Fares, Basem Fares, Naiel Azzam, Munir Nashashibi, Nevelsky Nevelsky, Stig Larsen and Steen Lindkær-Jensen

Radiation dermatitis occurs in up to 95 percent of patients receiving radiotherapy. The aim of this study was to evaluate whether topical application of a new Benzene-Poly-Carboxylic Acid and Molybdenum Complex (BP-C2) prophylactically could protect mice skin from irradiation-induced dermatitis or treat irradiation-induced skin dermatitis, when it already has occurred. The right posterior leg of male BALB/cfC3H mice was exposed to radiation dose of 30 Gy. For prevention studies, animals were treated with BP-C2 just prior to irradiation and three times a week for 5 weeks post-radiation. For treatment studies, animals were treated with PB-C2 three times a week for five weeks when skin injury was appeared following irradiation exposure. Animals were sacrificed and skin damage was assessed using a non-linear semi-quantitative scale, as well as histological studies. Acute skin dermatitis was observed in all control animals (n=8) following 30 Gy irradiation in form of edema and ulceration grade 4. No signs of skin dermatitis were observed in the irradiated area of animals (n=8) treated with BP-C2 prior to irradiation exposure. Moreover, treatment of injured animals with BP-C2 three times a week resulted in recovery of the skin and no erythema or ulceration was hereafter observed. BP-C2 represents a potentially promising agent for prevention and treatment of irradiation-induced skin dermatitis.